Do analysts recommend CASI or MBRX?

Moleculin Biotech has a consensus target price of $3.00, suggesting a potential upside of 476.92%. Given Moleculin Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Moleculin Biotech is more favorable than CASI Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CASI Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Moleculin Biotech 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Do analysts recommend CASI or ENSC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CASI Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Ensysce Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate OBSV or CASI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 CASI Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate CASI or TRAW?

Traws Pharma has a consensus price target of $1.00, suggesting a potential upside of 99.60%. Given Traws Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Traws Pharma is more favorable than CASI Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CASI Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Traws Pharma 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80

Do analysts prefer CNSP or CASI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CNS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CASI Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

CASI Pharmaceuticals (CASI) Competitors

$0.21 0.00 (0.00%)

As of 09/22/2026

Compare

CASI vs. MBRX, ENSC, OBSV, TRAW, and CNSP

Should you buy CASI Pharmaceuticals stock or one of its competitors? CASI Pharmaceuticals's main competitors and comparable companies include Moleculin Biotech (MBRX), Ensysce Biosciences (ENSC), ObsEva (OBSV), Traws Pharma (TRAW), and CNS Pharmaceuticals (CNSP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does CASI Pharmaceuticals compare to Moleculin Biotech?

CASI Pharmaceuticals (NASDAQ:CASI) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.

22.2% of CASI Pharmaceuticals shares are held by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are held by institutional investors. 21.2% of CASI Pharmaceuticals shares are held by company insiders. Comparatively, 18.0% of Moleculin Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Moleculin Biotech has a consensus target price of $3.00, suggesting a potential upside of 476.92%. Given Moleculin Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Moleculin Biotech is more favorable than CASI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Moleculin Biotech had 2 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 2 mentions for Moleculin Biotech and 0 mentions for CASI Pharmaceuticals. CASI Pharmaceuticals' average media sentiment score of 0.00 equaled Moleculin Biotech'saverage media sentiment score.

Company	Overall Sentiment
CASI Pharmaceuticals	Neutral
Moleculin Biotech	Neutral

Moleculin Biotech has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%. CASI Pharmaceuticals' return on equity of 0.00% beat Moleculin Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-183.93%	N/A	-131.54%
Moleculin Biotech	N/A	-143.51%	-24.53%

CASI Pharmaceuticals has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market. Comparatively, Moleculin Biotech has a beta of 1.92, suggesting that its share price is 92% more volatile than the broader market.

Moleculin Biotech has lower revenue, but higher earnings than CASI Pharmaceuticals. Moleculin Biotech is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A
Moleculin Biotech	N/A	N/A	-$33.56M	-$7.13	N/A

Summary

Moleculin Biotech beats CASI Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does CASI Pharmaceuticals compare to Ensysce Biosciences?

CASI Pharmaceuticals (NASDAQ:CASI) and Ensysce Biosciences (NASDAQ:ENSC) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.

In the previous week, Ensysce Biosciences had 1 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 1 mentions for Ensysce Biosciences and 0 mentions for CASI Pharmaceuticals. CASI Pharmaceuticals' average media sentiment score of 0.00 equaled Ensysce Biosciences'average media sentiment score.

Company	Overall Sentiment
CASI Pharmaceuticals	Neutral
Ensysce Biosciences	Neutral

CASI Pharmaceuticals has a net margin of -183.93% compared to Ensysce Biosciences' net margin of -280.53%. CASI Pharmaceuticals' return on equity of 0.00% beat Ensysce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-183.93%	N/A	-131.54%
Ensysce Biosciences	-280.53%	-2,550.30%	-320.49%

Ensysce Biosciences has lower revenue, but higher earnings than CASI Pharmaceuticals. Ensysce Biosciences is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A
Ensysce Biosciences	$5.07M	1.59	-$10.18M	-$2.76	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ensysce Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

22.2% of CASI Pharmaceuticals shares are held by institutional investors. Comparatively, 5.6% of Ensysce Biosciences shares are held by institutional investors. 21.2% of CASI Pharmaceuticals shares are held by insiders. Comparatively, 2.8% of Ensysce Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

CASI Pharmaceuticals has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market. Comparatively, Ensysce Biosciences has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market.

Summary

CASI Pharmaceuticals beats Ensysce Biosciences on 7 of the 12 factors compared between the two stocks.

How does CASI Pharmaceuticals compare to ObsEva?

ObsEva (NASDAQ:OBSV) and CASI Pharmaceuticals (NASDAQ:CASI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

17.5% of ObsEva shares are owned by institutional investors. Comparatively, 22.2% of CASI Pharmaceuticals shares are owned by institutional investors. 14.4% of ObsEva shares are owned by company insiders. Comparatively, 21.2% of CASI Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

CASI Pharmaceuticals has higher revenue and earnings than ObsEva. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, ObsEva's average media sentiment score of 0.00 equaled CASI Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
ObsEva	Neutral
CASI Pharmaceuticals	Neutral

ObsEva has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%. CASI Pharmaceuticals' return on equity of 0.00% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ObsEva	N/A	-416.36%	-92.01%
CASI Pharmaceuticals	-183.93%	N/A	-131.54%

ObsEva has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market. Comparatively, CASI Pharmaceuticals has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market.

Summary

CASI Pharmaceuticals beats ObsEva on 7 of the 11 factors compared between the two stocks.

How does CASI Pharmaceuticals compare to Traws Pharma?

CASI Pharmaceuticals (NASDAQ:CASI) and Traws Pharma (NASDAQ:TRAW) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation.

CASI Pharmaceuticals has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market. Comparatively, Traws Pharma has a beta of 1.6, indicating that its stock price is 60% more volatile than the broader market.

Traws Pharma has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%. CASI Pharmaceuticals' return on equity of 0.00% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-183.93%	N/A	-131.54%
Traws Pharma	N/A	-23,868.92%	-165.52%

22.2% of CASI Pharmaceuticals shares are held by institutional investors. Comparatively, 8.0% of Traws Pharma shares are held by institutional investors. 21.2% of CASI Pharmaceuticals shares are held by company insiders. Comparatively, 7.6% of Traws Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Traws Pharma has lower revenue, but higher earnings than CASI Pharmaceuticals. Traws Pharma is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A
Traws Pharma	$2.79M	2.76	$9.17M	-$1.74	N/A

In the previous week, Traws Pharma had 2 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 2 mentions for Traws Pharma and 0 mentions for CASI Pharmaceuticals. CASI Pharmaceuticals' average media sentiment score of 0.00 equaled Traws Pharma'saverage media sentiment score.

Company	Overall Sentiment
CASI Pharmaceuticals	Neutral
Traws Pharma	Neutral

Traws Pharma has a consensus price target of $1.00, suggesting a potential upside of 99.60%. Given Traws Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Traws Pharma is more favorable than CASI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Traws Pharma	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Summary

Traws Pharma beats CASI Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does CASI Pharmaceuticals compare to CNS Pharmaceuticals?

CNS Pharmaceuticals (NASDAQ:CNSP) and CASI Pharmaceuticals (NASDAQ:CASI) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

CNS Pharmaceuticals has a beta of 3.06, meaning that its stock price is 206% more volatile than the broader market. Comparatively, CASI Pharmaceuticals has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market.

In the previous week, CNS Pharmaceuticals' average media sentiment score of 0.00 equaled CASI Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
CNS Pharmaceuticals	Neutral
CASI Pharmaceuticals	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

CNS Pharmaceuticals has higher earnings, but lower revenue than CASI Pharmaceuticals. CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$23.59	N/A
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A

CNS Pharmaceuticals has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%. CASI Pharmaceuticals' return on equity of 0.00% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CNS Pharmaceuticals	N/A	-204.25%	-141.87%
CASI Pharmaceuticals	-183.93%	N/A	-131.54%

14.0% of CNS Pharmaceuticals shares are held by institutional investors. Comparatively, 22.2% of CASI Pharmaceuticals shares are held by institutional investors. 1.8% of CNS Pharmaceuticals shares are held by company insiders. Comparatively, 21.2% of CASI Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

CASI Pharmaceuticals beats CNS Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

Get CASI Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CASI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CASI vs. The Competition

Export

Metric	CASI Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.55M	$12.59B	$7.31B	$13.28B
Dividend Yield	N/A	2.63%	2.52%	12.56%
P/E Ratio	-0.07	792.28	274.07	25.70
Price / Sales	0.10	857.34	673.22	90.62
Price / Cash	N/A	88.64	77.80	52.76
Price / Book	1.73	10.58	10.38	6.32
Net Income	-$39.26M	$2.81B	$3.49B	$359.73M
7 Day Performance	N/A	-0.16%	-0.69%	0.17%
1 Month Performance	N/A	-1.38%	-3.19%	-3.27%
1 Year Performance	-86.87%	2.83%	15.12%	5.58%

CASI Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CASI CASI Pharmaceuticals	N/A	$0.21 flat	N/A	N/A	$2.55M	$26.85M	N/A	180
MBRX Moleculin Biotech	3.0936 of 5 stars	$0.57 +8.6%	$3.00 +431.0%	-95.1%	$10.13M	N/A	N/A	17	News Coverage Gap Up High Trading Volume
ENSC Ensysce Biosciences	0.7498 of 5 stars	$0.43 +1.9%	N/A	-80.5%	$8.19M	$5.07M	N/A	10	News Coverage
OBSV ObsEva	N/A	N/A	N/A	N/A	$7.94M	N/A	N/A	50
TRAW Traws Pharma	1.3378 of 5 stars	$0.50 +0.0%	$1.00 +100.0%	-73.2%	$7.68M	$2.79M	N/A	7	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CASI) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CASI Pharmaceuticals (CASI) Competitors

CASI vs. MBRX, ENSC, OBSV, TRAW, and CNSP

How does CASI Pharmaceuticals compare to Moleculin Biotech?

Summary

How does CASI Pharmaceuticals compare to Ensysce Biosciences?

Summary

How does CASI Pharmaceuticals compare to ObsEva?

Summary

How does CASI Pharmaceuticals compare to Traws Pharma?

Summary

How does CASI Pharmaceuticals compare to CNS Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CASI vs. The Competition

CASI Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CASI Pharmaceuticals (CASI) Competitors

CASI vs. MBRX, ENSC, OBSV, TRAW, and CNSP

How does CASI Pharmaceuticals compare to Moleculin Biotech?

Do institutionals & insiders have more ownership in CASI or MBRX?

Do analysts recommend CASI or MBRX?

Does the media favor CASI or MBRX?

Is CASI or MBRX more profitable?

Which has more volatility and risk, CASI or MBRX?

Which has better earnings and valuation, CASI or MBRX?

Summary

How does CASI Pharmaceuticals compare to Ensysce Biosciences?

Does the media refer more to CASI or ENSC?

Is CASI or ENSC more profitable?

Which has preferable valuation & earnings, CASI or ENSC?

Do analysts recommend CASI or ENSC?

Do insiders and institutionals have more ownership in CASI or ENSC?

Which has more risk and volatility, CASI or ENSC?

Summary

How does CASI Pharmaceuticals compare to ObsEva?

Do institutionals & insiders hold more shares of OBSV or CASI?

Which has better earnings & valuation, OBSV or CASI?

Do analysts rate OBSV or CASI?

Does the media prefer OBSV or CASI?

Is OBSV or CASI more profitable?

Which has more volatility & risk, OBSV or CASI?

Summary

How does CASI Pharmaceuticals compare to Traws Pharma?

Which has more risk & volatility, CASI or TRAW?

Is CASI or TRAW more profitable?

Do institutionals & insiders have more ownership in CASI or TRAW?

Which has better earnings and valuation, CASI or TRAW?

Does the media refer more to CASI or TRAW?

Do analysts rate CASI or TRAW?

Summary

How does CASI Pharmaceuticals compare to CNS Pharmaceuticals?

Which has more volatility and risk, CNSP or CASI?

Does the media prefer CNSP or CASI?

Do analysts prefer CNSP or CASI?

Which has higher earnings and valuation, CNSP or CASI?

Is CNSP or CASI more profitable?

Do insiders & institutionals believe in CNSP or CASI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CASI vs. The Competition

CASI Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools